Radiology

Your Article Summary

See Latest Articles

Recommendations on the use of 18F-FDG PET in oncology
The Journal of Nuclear Medicine, 03/10/08

Fletcher JW et al. - In a trial to develop recommendations on use of 18F-FDG PET in breast, colorectal, esophageal, head and neck, lung, pancreatic, and thyroid cancer; lymphoma, melanoma, and sarcoma; and unknown primary tumor, it was recommended that 18F-FDG PET should be used as an imaging tool in addition to conventional radiologic methods such as CT or MRI

• A search was performed to identify all published randomized controlled trials and systematic reviews in the literature
• An additional search was performed to identify relevant unpublished systematic reviews
• Publications comprised both retrospective and prospective studies of varied methodologic quality
• Anticipated consequences of false-positive and false-negative tests when evaluating clinical usefulness, and impact of 18F-FDG PET on management of cancer pts, were also reviewed

• 18F-FDG PET should be used as an imaging tool in addition to conventional radiologic methods such as CT or MRI
• Any positive finding that could lead to a clinically significant change in pt management should be confirmed by subsequent histopathologic examination because of the risk of false-positive results
• 18F-FDG PET should be used in the appropriate clinical setting for the diagnosis of head and neck, lung, or pancreatic cancer and for unknown primary tumor

Today in Nuclear Medicine...keeping you current

Receive free subspecialty "5-minute updates" via email

Prostate Cancer: Role of SPECT and PET in Imaging Bone Metastases
Seminars in Nuclear Medicine, 10/09/09

Breast Cancer: Role of SPECT and PET in Imaging Bone Metastases
Seminars in Nuclear Medicine, 10/14/09

Prediction model of chemotherapy response in osteosarcoma by 18F-FDG PET and MRI
The Journal of Nuclear Medicine, 08/19/09

See All of Nuclear Medicine